Product category:
Contract research
News Release from: Lab21 | Subject: Lab21
Edited by the Laboratorytalk Editorial
Team on 26 July 2005
Antiviral drug discovery and clinical
trials
Array of spearhead tests and services available include lead identification and optimisation, resistance profiling, clinical candidate selection and selectivity evaluation in pre-clinical situations
A new company - Lab21 - has been launched to provide technically advanced drug discovery and clinical trials services to the pharmaceutical and biotech industries Testing is performed in state-of-the-art laboratories in Cambridge, UK, with commercial headquarters in Fareham, UK
This article was originally published on Laboratorytalk on 13 Dec 2006 at 8.00am (UK)
Related stories
Cardiac channelopathy genetic tests in UK, Ireland
Lab21 to market and sell Clinical Data's Familion, a genetic test designed to identify mutations in people with inherited cardiac channelopathies such as Long QT Syndrome (LQTS) and Brugada Syndrome
Thrombotic disease tests 'could save lives'
These thrombotic tests build on Lab21's portfolio of diagnostics for personalised medicine, adding to tests for heart disease, liver disease, cystic fibrosis and Sids (sudden infant death syndrome)
Lab21 brings together high level drug discovery experience, expert know-how and an unmatched range of superior testing technologies - all delivered with the demands of the regulatory bodies in mind, it says.
An extensive array of spearhead tests and services are available including lead identification and optimisation, resistance profiling, clinical candidate selection and selectivity evaluation in pre-clinical situations.
And once a drug is in the clinic, Lab21 offers pharmacogenetic testing and trial stratification, FDA requirements for registration, efficacy studies and resistance monitoring.
Lab21 claims to be the only company of its kind in the UK.
Supported financially by Merlin Biosciences, Merlin's chairman, Professor Sir Christopher Evans, leads the Lab21 board of directors.
Many industry leaders foresee a more effective and efficient future for healthcare delivery.
A time when pharmacogenetic profiling will allow prediction of the risk of certain diseases or conditions developing, and we reach a full understanding of the impact an individual's genetic make-up, lifestyle choices and environmental factors can have on disease progression and response to therapy.
Nick Kerton, CEO of Lab21, commented: "We believe that Lab21 has already made significant progress towards the goal of personalised healthcare.
"Our customers can benefit today from a unique portfolio of tests that allow the characterisation of a virus, the assessment of prospective drug candidates, and the understanding of potential resistance.
"In addition, we can genotype a trials population, assess their pharmacogenetics, or monitor patients undergoing therapy.".
• Lab21: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
